[go: up one dir, main page]

NO960723L - Inhibitorer for TNF-alfa-sekresjon - Google Patents

Inhibitorer for TNF-alfa-sekresjon

Info

Publication number
NO960723L
NO960723L NO960723A NO960723A NO960723L NO 960723 L NO960723 L NO 960723L NO 960723 A NO960723 A NO 960723A NO 960723 A NO960723 A NO 960723A NO 960723 L NO960723 L NO 960723L
Authority
NO
Norway
Prior art keywords
tnf
inhibitors
alpha secretion
tace
compounds
Prior art date
Application number
NO960723A
Other languages
English (en)
Norwegian (no)
Other versions
NO960723D0 (no
Inventor
Roy Alvin Black
Jeffrey Neal Fitzner
Paul Ronald Sleath
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Publication of NO960723L publication Critical patent/NO960723L/no
Publication of NO960723D0 publication Critical patent/NO960723D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • C07K5/06095—Arg-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Extrusion Moulding Of Plastics Or The Like (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
NO960723A 1993-08-23 1996-02-23 Inhibitorer for TNF-alfa-sekresjon NO960723D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11060193A 1993-08-23 1993-08-23
US18301994A 1994-01-18 1994-01-18
PCT/US1994/009343 WO1995006031A1 (en) 1993-08-23 1994-08-19 Inhibitors of tnf-alpha secretion

Publications (2)

Publication Number Publication Date
NO960723L true NO960723L (no) 1996-02-23
NO960723D0 NO960723D0 (no) 1996-02-23

Family

ID=26808203

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960723A NO960723D0 (no) 1993-08-23 1996-02-23 Inhibitorer for TNF-alfa-sekresjon

Country Status (8)

Country Link
EP (1) EP0715619A4 (fi)
JP (1) JPH09503201A (fi)
AU (2) AU687436B2 (fi)
CA (1) CA2170158A1 (fi)
FI (1) FI960803L (fi)
NO (1) NO960723D0 (fi)
NZ (1) NZ271893A (fi)
WO (1) WO1995006031A1 (fi)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0784629T3 (da) 1994-10-05 1999-10-25 Darwin Discovery Ltd Peptidylforbindelser og deres terapeutiske anvendelse som inhibitorer af metalloproteaser
JPH11504646A (ja) * 1995-05-10 1999-04-27 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチド化合物およびその治療的使用
ATE237630T1 (de) * 1995-05-10 2003-05-15 Darwin Discovery Ltd Peptidartige stoffe, die metalloproteinasen und die tnf-freisetzung hemmen, und ihre therapeutische verwendung
JPH11505532A (ja) * 1995-05-10 1999-05-21 カイロサイエンス・リミテッド 金属プロテアーゼとｔｎｆの放出を抑制するペプチド化合物およびその治療的使用
US6406901B1 (en) 1995-06-08 2002-06-18 Immunex Corporation TNF-a converting enzyme
WO1997009420A2 (en) * 1995-09-05 1997-03-13 Celltech Therapeutics Limited Dna sequences coding for a human metalloproteinase and variants thereof
CN1145637C (zh) * 1995-10-05 2004-04-14 达尔文发现有限公司 作为金属蛋白酶和tnf释放抑制剂的硫取代的肽
US5665777A (en) * 1995-11-14 1997-09-09 Abbott Laboratories Biphenyl hydroxamate inhibitors of matrix metalloproteinases
US6127427A (en) 1995-11-23 2000-10-03 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
GB9607120D0 (en) * 1996-04-04 1996-06-12 Chiroscience Ltd Compounds
US5990293A (en) * 1996-09-05 1999-11-23 Celltech Therapeutics Limited Human metalloproteinase, variants thereof and DNA sequence coding therefor
CZ298048B6 (cs) 1996-09-10 2007-06-06 British Biotech Pharmaceuticals Limited Farmaceutický prostredek a deriváty kyseliny hydroxamové
US6462023B1 (en) 1996-09-10 2002-10-08 British Biotech Pharmaceuticals, Ltd. Cytostatic agents
ZA9818B (en) * 1997-01-07 1998-07-02 Abbott Lab C-terminal ketone inhibitors of matrix metalloproteinases and tnf alpha secretion
US5985911A (en) * 1997-01-07 1999-11-16 Abbott Laboratories C-terminal ketone inhibitors of matrix metalloproteinases and TNFα secretion
US5952320A (en) * 1997-01-07 1999-09-14 Abbott Laboratories Macrocyclic inhibitors of matrix metalloproteinases and TNFα secretion
WO1998057657A1 (en) * 1997-06-18 1998-12-23 The Rockefeller University Methods for identifying antibodies and peptides useful in the treatment of septic shock and experimental arthritis and uses thereof
AU9449398A (en) * 1997-10-10 1999-05-03 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
GB9810464D0 (en) 1998-05-16 1998-07-15 British Biotech Pharm Hydroxamic acid derivatives
GB9818605D0 (en) 1998-08-26 1998-10-21 Glaxo Group Ltd Formamide compounds as therepeutic agents
US6172064B1 (en) 1998-08-26 2001-01-09 Glaxo Wellcome Inc. Formamides as therapeutic agents
US6329400B1 (en) 1998-08-26 2001-12-11 Glaxo Wellcome Inc. Formamide compounds as therapeutic agents
AU6060299A (en) * 1998-09-30 2000-04-17 Procter & Gamble Company, The Method of treating hair loss using ketoamides
US6300341B1 (en) 1998-09-30 2001-10-09 The Procter & Gamble Co. 2-substituted heterocyclic sulfonamides
BR9914196A (pt) * 1998-09-30 2001-06-19 Procter & Gamble Processo de tratamento da perda de cabelo
US6307049B1 (en) 1998-09-30 2001-10-23 The Procter & Gamble Co. Heterocyclic 2-substituted ketoamides
US6288261B1 (en) 1998-12-18 2001-09-11 Abbott Laboratories Inhibitors of matrix metalloproteinases
US6329550B1 (en) 1998-12-31 2001-12-11 Aventis Pharmaceuticals Inc. Amidomalonamides useful as inhibitors of MMP of matrix metalloproteinase
JP2002534440A (ja) * 1999-01-13 2002-10-15 ヨマー、ファルマカ、ゲゼルシャフト、ミット、ベシュレンクテル、ハフツング 感染症の治療のための３−イソキサゾリジノンおよびヒドロキシルアミン酸の使用
US20040220103A1 (en) 1999-04-19 2004-11-04 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders
GB9922825D0 (en) * 1999-09-25 1999-11-24 Smithkline Beecham Biolog Medical use
AU2001271068A1 (en) * 2000-07-18 2002-01-30 Chugai Seiyaku Kabushiki Kaisha Matrix metalloprotease inhibitors
AU2002230385A1 (en) * 2000-09-25 2002-04-15 Questcor Pharmaceuticals, Inc. Peptide deformylase inhibitors
PE20030701A1 (es) 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
EP3860608A1 (en) 2018-10-04 2021-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Egfr inhibitors for treating keratodermas

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0207097B1 (de) * 1984-12-19 1990-08-08 Ciba-Geigy Ag Neue kohlensäureester
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
WO1992022523A2 (en) * 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9323165D0 (en) * 1993-11-10 1994-01-05 Chiros Ltd Compounds
GB9411088D0 (en) * 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives

Also Published As

Publication number Publication date
EP0715619A4 (en) 1997-03-19
CA2170158A1 (en) 1995-03-02
AU5030298A (en) 1998-03-05
WO1995006031A1 (en) 1995-03-02
EP0715619A1 (en) 1996-06-12
AU7569494A (en) 1995-03-21
FI960803A0 (fi) 1996-02-22
JPH09503201A (ja) 1997-03-31
NZ271893A (en) 1997-11-24
NO960723D0 (no) 1996-02-23
AU687436B2 (en) 1998-02-26
FI960803A7 (fi) 1996-04-22
FI960803L (fi) 1996-04-22

Similar Documents

Publication Publication Date Title
NO960723L (no) Inhibitorer for TNF-alfa-sekresjon
MY129998A (en) Saccharin derivative proteolytic enzyme inhibitors
Harris et al. Pseudosubstrate inhibition of cyclic AMP-dependent protein kinase in intact pancreatic islets: effects on cyclic AMP-dependent and glucose-dependent insulin secretion
MY110104A (en) Saccharin derivative proteolytic enzyme inhibitors
DK204290D0 (da) Enzymatisk detergentkomposition og fremgangsmaade til enzymstabilisering
AU2003282920A1 (en) Hydantoin derivatives as inhibitors of matrix metalloproteinases and/or tnf-alpha converting enzyme (tace)
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
BR9908280A (pt) Inibidores de enzimas de fosfolipase
AU2002357312A1 (en) Barbituric acid derivatives as inhibitors of tnf-alpha converting enzyme (tace) and/or matrix metalloproteinases
EP1289559B8 (de) Kombinationen von enzyminhibitoren umfassende zubereitungen und deren verwendung
HUP9900816A2 (hu) Piperidin-karbonsav-származékok alkalmazása rotamáz enzim inhibitor hatású gyógyszerkészítmények előállítására
AU3856497A (en) Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
AU2001248701A1 (en) Inhibitors of histone deacetylase
DK0719154T3 (da) Aktiveret faktor VIII som terapeutisk middel og metode til behandling af faktor VIII-mangel
MY100641A (en) Neutral metalloendopeptidase inhibitors in the treatment of hypertension.
NZ503962A (en) ACE inhibitor (angiotensin converting enzyme) and MMP (matrix metalloproteinase inhibitor) combinations for treating fibrosis
van der Zee et al. Cytokine‐induced endogenous procollagenase stored in the extracellular matrix of soft connective tissue results in a burst of collagen breakdown following its activation
NO964416L (no) Fremgangsmåter for å fremstille effektive rekombinante serin protease inhibitorer og anvendelser av disse inhibitorene
NO914217D0 (no) Sakkarinderivater nyttige som proteolytiske enzyminhibitorer og fremstilling derav
AU6458396A (en) Phosphorous-containing cysteine and serine protease inhibitors
AU2002325782A1 (en) Pharmaceutical composition and method of treatment of human malignancies with arginine deprivation
AU2158200A (en) Novel inhibitors of farnesyl-protein transferase
MURACHI et al. Inhibition of stem bromelain by the chloromethyl ketone derivatives of N-tosyl-L-phenylalanine and N-tosyl-L-lysine
Petrovan et al. Purification and characterization of multisquamase, the prothrombin activator present in Echis multisquamatus venom
Girish et al. A low molecular weight isoform of hyaluronidase: purification from Indian cobra (Naja naja) venom and partial characterization